This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parekh, H. K. Articles by Simpkins, H. Search for Related Content PubMed PubMed Citation Articles by Parekh, H. K. Articles by Simpkins, H.

The Differential Expression of Cytokeratin 18 in Cisplatin-sensitive and -resistant Human Ovarian Adenocarcinoma Cells and Its Association with Drug Sensitivity

Department of Pathology, Temple University School of Medicine and Fels Institute of Molecular Biology and Cancer Research, Philadelphia, Pennsylvania 19140

DNA is the primary target of cis-diamminedichloroplatinum (cisplatin), but the drug also interacts with the cellular cytoskeleton composed of microtubules and intermediate filaments. It was found that the cisplatin-resistant 2008/C13* cell line contained markedly lower levels (6-fold) of cytokeratin 18, when compared to the cisplatin-sensitive 2008 cell line. Northern blot analysis revealed a markedly decreased level of cytokeratin 18 mRNA in the resistant cell line. Southern blot analysis of the DNA extracted from the two cell lines and then digested with HpaII and its methylation-sensitive isoschizomer, MspI, revealed no detectable differences in the methylation status of the cytokeratin gene. Neither 5-azacytidine (5 µM) nor retinoic acid (1 µM) treatment enhanced the expression of cytokeratin 18 in the resistant cell line. However, transfection of full-length cytokeratin 18 cDNA into the cisplatin-resistant 2008/C13* cells resulted in clones with increased levels of cytokeratin 18, which was accompanied in the majority of clones by a marked increase in their sensitivity to cisplatin. These results demonstrate that modulating the expression of an intermediate filament protein results in sensitization of a drug-resistant human ovarian cell line to cisplatin.

¹ To whom requests for reprints should be addressed, at Department of Pathology, Temple University School of Medicine, Room 106 OMS, 3400 North Broad Street, Philadelphia, PA 19140. Phone: (215) 707-4353; Fax: (215) 707-2781.

Received 6/19/95. Accepted 10/ 5/95.

This article has been cited by other articles:

				V. Poindessous, F. Koeppel, E. Raymond, M. Comisso, S. J. Waters, and A. K. Larsen Marked Activity of Irofulven toward Human Carcinoma Cells: Comparison with Cisplatin and Ecteinascidin Clin. Cancer Res., July 1, 2003; 9(7): 2817 - 2825. [Abstract] [Full Text] [PDF]

				D. Jaquemar, S. Kupriyanov, M. Wankell, J. Avis, K. Benirschke, H. Baribault, and R. G. Oshima Keratin 8 protection of placental barrier function J. Cell Biol., May 26, 2003; 161(4): 749 - 756. [Abstract] [Full Text] [PDF]

				H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells J. Biol. Chem., April 19, 2002; 277(17): 15035 - 15043. [Abstract] [Full Text] [PDF]

				C. Caulin, G. S. Salvesen, and R. G. Oshima Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis J. Cell Biol., September 22, 1997; 138(6): 1379 - 1394. [Abstract] [Full Text] [PDF]

				H. Eto, S. S. Yoon, B. P. Bode, S. Kamidono, K. Makino, H. Saya, H. Nakamura, and K. K. Tanabe Mapping and Regulation of the Tumor-associated Epitope Recognized by Monoclonal Antibody RS-11 J. Biol. Chem., August 25, 2000; 275(35): 27075 - 27083. [Abstract] [Full Text] [PDF]